[
  {
    "ts": null,
    "headline": "Fanconi Anemia Market Research Report 2025-2035: Competitive Growth Driven by Rocket Pharmaceuticals, Foresee, Merck, and Abeona as Gene Therapy and CRISPR-Based Innovations Expand",
    "summary": "**Fanconi Anemia Market Growth Driven by Genetic Research and Healthcare Investments**Fanconi Anemia (FA) is a rare genetic disorder impacting bone marrow's ability to produce blood cells, leading to pancytopenia and increased cancer risk due to DNA repair defects. Although incurable, treatments like bone marrow transplants and gene therapy aim to manage FA's symptoms. The rising prevalence of genetic disorders and advancements in genetic research drive the FA market. Key players such as Rocket",
    "url": "https://finnhub.io/api/news?id=c86b2cea0916e9dc6a0e599f786da35bd7cc52c4e31618aa59598bfbd6015dcf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763478960,
      "headline": "Fanconi Anemia Market Research Report 2025-2035: Competitive Growth Driven by Rocket Pharmaceuticals, Foresee, Merck, and Abeona as Gene Therapy and CRISPR-Based Innovations Expand",
      "id": 137538304,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "**Fanconi Anemia Market Growth Driven by Genetic Research and Healthcare Investments**Fanconi Anemia (FA) is a rare genetic disorder impacting bone marrow's ability to produce blood cells, leading to pancytopenia and increased cancer risk due to DNA repair defects. Although incurable, treatments like bone marrow transplants and gene therapy aim to manage FA's symptoms. The rising prevalence of genetic disorders and advancements in genetic research drive the FA market. Key players such as Rocket",
      "url": "https://finnhub.io/api/news?id=c86b2cea0916e9dc6a0e599f786da35bd7cc52c4e31618aa59598bfbd6015dcf"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)",
    "summary": "RAHWAY, N.J., November 18, 2025--Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF",
    "url": "https://finnhub.io/api/news?id=f50213c5a244f43de3ee78c456e5f2d7b87ba16a43db2537d0f8c964b843ff75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763466300,
      "headline": "Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)",
      "id": 137538305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 18, 2025--Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF",
      "url": "https://finnhub.io/api/news?id=f50213c5a244f43de3ee78c456e5f2d7b87ba16a43db2537d0f8c964b843ff75"
    }
  },
  {
    "ts": null,
    "headline": "Is Merck's Recent FDA Approval a Game Changer for Its Share Price?",
    "summary": "Thinking about whether Merck is a bargain or not? You’re not alone, plenty of investors are eager to know if now is the time to buy, hold, or stay away. Over the last month, Merck’s share price has jumped 9.5% and gained 7.0% this week alone, even though it’s still down 6.4% year-to-date. Recent headlines have highlighted Merck’s expanding drug pipeline and a new FDA approval, fueling a bit of optimism and helping offset earlier caution in the market. These developments have given more...",
    "url": "https://finnhub.io/api/news?id=39e1a7b22f2596d4baec81527836e8a70ff247d39b9beb8b5d5a4ebbc23e999e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763464122,
      "headline": "Is Merck's Recent FDA Approval a Game Changer for Its Share Price?",
      "id": 137538306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Thinking about whether Merck is a bargain or not? You’re not alone, plenty of investors are eager to know if now is the time to buy, hold, or stay away. Over the last month, Merck’s share price has jumped 9.5% and gained 7.0% this week alone, even though it’s still down 6.4% year-to-date. Recent headlines have highlighted Merck’s expanding drug pipeline and a new FDA approval, fueling a bit of optimism and helping offset earlier caution in the market. These developments have given more...",
      "url": "https://finnhub.io/api/news?id=39e1a7b22f2596d4baec81527836e8a70ff247d39b9beb8b5d5a4ebbc23e999e"
    }
  },
  {
    "ts": null,
    "headline": "Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?",
    "summary": "Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at RXRX stock and its latest earnings.",
    "url": "https://finnhub.io/api/news?id=07ff206a122b4ea7729f18bab5dce1dcb5e21779ca9765eebb0e4c3588fb62de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763460874,
      "headline": "Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?",
      "id": 137538047,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412857430/image_1412857430.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at RXRX stock and its latest earnings.",
      "url": "https://finnhub.io/api/news?id=07ff206a122b4ea7729f18bab5dce1dcb5e21779ca9765eebb0e4c3588fb62de"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.",
    "url": "https://finnhub.io/api/news?id=10e4f4a6238a1404fc41578349c3fefd3a6088b212b55815a92542bbea1bf70a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763454600,
      "headline": "[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)",
      "id": 137538307,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.",
      "url": "https://finnhub.io/api/news?id=10e4f4a6238a1404fc41578349c3fefd3a6088b212b55815a92542bbea1bf70a"
    }
  },
  {
    "ts": null,
    "headline": "Merck Has Many Bullish Attributes (Technical Analysis)",
    "summary": "Merck has bullish valuation metrics and is trading above its 30-week EMA with bullish long-term momentum. Learn why MRK stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=f0adbb55f599a0fcd3524f0daae35b81f6412365130e5dafbaf4816795420b35",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763439516,
      "headline": "Merck Has Many Bullish Attributes (Technical Analysis)",
      "id": 137528603,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck has bullish valuation metrics and is trading above its 30-week EMA with bullish long-term momentum. Learn why MRK stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=f0adbb55f599a0fcd3524f0daae35b81f6412365130e5dafbaf4816795420b35"
    }
  },
  {
    "ts": null,
    "headline": "MoonLake: Ignore The Panic, Catch The Upside",
    "summary": "MoonLake Immunotherapeutics (MLTX) offers strong investment potential with key clinical trials and upcoming FDA milestones. See more analysis here.",
    "url": "https://finnhub.io/api/news?id=5ab285960ac00fad69ad86ded3f7a0e5e1587157cf0c24fc675316ec65f4b4b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763426016,
      "headline": "MoonLake: Ignore The Panic, Catch The Upside",
      "id": 137522373,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1169172674/image_1169172674.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "MoonLake Immunotherapeutics (MLTX) offers strong investment potential with key clinical trials and upcoming FDA milestones. See more analysis here.",
      "url": "https://finnhub.io/api/news?id=5ab285960ac00fad69ad86ded3f7a0e5e1587157cf0c24fc675316ec65f4b4b5"
    }
  }
]